Blood Vessels Thrombosis & HemostasisCell BiologyPeer-reviewed journal article
An angiopoietin-2 vaccine improves arteriovenous malformation pathology in hereditary hemorrhagic telangiectasia mice
Sima QutainaiD, Haitian ZHAOiD, Zhiming WangiD, Caterina IvaldoiD, Santiago RuiziD, Andy Sullivan, Erin Murphy, Philippe MarambaudiD
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a genetic vascular disorder that causes systemic arteriovenous malformations (AVMs) associated with severe complications. Angiopoietin (ANG)-2 has been identified as a consistently upregulated secreted protein across various HHT models, and neutralizing ANG2 reduces AVMs in mice. ANG2 has thus emerged as a potential target for HHT treatment. Here, we report the development of a peptide vaccine (ANG2-P3:CRM197) that selectively targets ANG2 over ANG1 and tested its effectiveness in decreasing retinal AVMs in neonatal mice injected with BMP9/10 blocking antibodies, a model of HHT. Litter groups from female C57BL/6 mice immunized with ANG2-P3:CRM197 received injections of anti-BMP9/10 antibodies, and their retinas were examined for vascular pathology. The potential toxicity of the vaccine was evaluated in females 12 months post-immunization through echocardiography, basic metabolic panels, and lipid profiles. Circulating anti-ANG2 antibodies were detected in nursing neonates of vaccinated females, with antibody levels comparable between litters and their dams, indicating effective antibody transfer from the dams. A significant decrease in AVM number and size was observed in the retinas of pups exposed to ANG2-P3:CRM197 antibodies compared to unexposed pups. Arterial and venous diameters were normalized in the vaccinated pups retinas. The vaccinated females showed no abnormalities in cardiac, liver, or kidney functions. A vaccine strategy targeting ANG2 appears safe and improves AVM pathology in HHT mice. These findings further support the potential of inhibiting ANG2 as a viable approach for treating AVMs in HHT. KEY POINTSO_LIA peptide vaccine that targets ANG2 reduced AVM number and size, and normalized arterial and venous diameters in a mouse model of HHT. C_LIO_LIThe vaccine did not cause any abnormalities in cardiac, liver, or kidney functions, and thus appeared safe. C_LI
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 2
- FWCI
- 8.91
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10
S. Ruiz, H. Zhao, … P. Marambaud·bioRxiv·Nov 2, 2016
- ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia
Sima Qutaina, Haitian Zhao, … Philippe Marambaud·bioRxiv·Aug 13, 2025
- PIEZO1 overexpression in hereditary hemorrhagic telangiectasia arteriovenous malformations
Hyojin Park, Sungwoon Lee, … Anne Eichmann·CirculationPeer-reviewed·Jul 16, 2025
- Modeling Somatic Second-Hit Mutations in Novel Mouse Models of Hereditary Hemorrhagic Telangiectasia
Adella P. Guidroz, Shreya Bavishi, … Stryder M. Meadows·bioRxiv·Feb 22, 2026
- Sirolimus plus nintedanib treats vascular pathology in HHT mouse models
S. Ruiz, H. Zhao, … P. Marambaud·bioRxiv·Aug 18, 2019
- Defective flow-migration coupling causes arteriovenous malformations in hereditary hemorrhagic telangiectasia
H. Park, J. Furtado, … A. Eichmann·bioRxiv·May 6, 2021